Wild poliovirus has remained endemic in northern Nigeria because of low coverage achieved in the routine immunization program and in supplementary immunization activities (SIAs). An outbreak of infection involving 315 cases of type 2 circulating vaccine-derived poliovirus (cVDPV2; .1% divergent from Sabin 2) occurred during July 2005-June 2010, a period when 23 of 34 SIAs used monovalent or bivalent oral poliovirus vaccine (OPV) lacking Sabin 2. In addition, 21 ''pre-VDPV2'' (0.5%-1.0% divergent) cases occurred during this period. Both cVDPV and pre-VDPV cases were clinically indistinguishable from cases due to wild poliovirus. The monthly incidence of cases increased sharply in early 2009, as more children aged without trivalent OPV SIAs. Cumulative state incidence of pre-VDPV2/cVDPV2 was correlated with low childhood immunization against poliovirus type 2 assessed by various means. Strengthened routine immunization programs in countries with suboptimal coverage and balanced use of OPV formulations in SIAs are necessary to minimize risks of VDPV emergence and circulation.
The cornerstone of the Global Polio Eradication Initiative is immunization of children with multiple doses of oral poliovirus vaccine (OPV), via both routine immunization (RI) and supplementary immunization activities (SIAs) [1] . The key advantages of OPV are ease of administration and efficient induction of mucosal immunity, thereby limiting poliovirus shedding and person-to-person transmission [2] . Through widespread implementation of this approach and with standardized virologic surveillance, indigenous wild poliovirus (WPV) transmission has stopped in all but 4 countries (Nigeria, Pakistan, Afghanistan, and India) [1] . WPV type 2 (WPV2) circulation apparently stopped in Africa in the mid-1990s (F. Adu and C. Koffi; unpublished data), and WPV2 was last detected (in India) in 1999 [3] .
Despite its advantages, OPV use carries the infrequent risks of vaccine-associated paralytic poliomyelitis among OPV recipients and their direct contacts [2] and the emergence of genetically divergent vaccine-derived polioviruses (VDPVs) [4, 5] , both a consequence of selection against the attenuated phenotype during intestinal replication [6] . VDPVs are operationally defined as OPV-related isolates having .1% nucleotide (nt) sequence divergence from the parental OPV strain in the 900-nt region encoding the major capsid surface protein, VP1 [4, 5] . This arbitrary demarcation represents 1 year of poliovirus (PV) replication after administration of the initiating OPV dose [7] , substantially longer than the normal postvaccination excretion period of 4-6 weeks [2, 8] . VDPVs are further categorized as circulating (cVDPVs) when there is clear evidence of transmission beyond close contacts [4, 5] . cVDPV outbreaks have occurred in settings of widening susceptibility to >1 poliovirus serotype in association with weak RI programs and in locations where the corresponding WPVs of the same serotype have been eliminated [4, 5, 9, 10] . The risk of cVDPV emergence appears to be highest for the Sabin type 2 (Sabin 2) OPV strain [4, 5, 10] , particularly in areas with high densities of nonimmune persons, poor sanitation, and tropical or subtropical climates [11] .
Northern Nigeria had remained a major reservoir for WPV1 and WPV3 [12, 13] In 2002, a case involving VDPV type 2 (VDPV2) was detected in Plateau state, but no related cases involving VDPV2 or any other VDPVs were detected over the next 4 years [16] . In August 2006, virologic investigations detected a cluster of acute flaccid paralysis (AFP) cases associated with Sabin 2-related isolates in northern Nigeria; sequence analysis revealed that the isolates were VDPVs [17] . Retrospective analyses found an early outbreak isolate in 2005, and continued screening through mid-2010 detected a total of 315 VDPV2 case isolates. We found an additional 21 cases with ''pre-VDPV2'' isolates (0.5%-1% VP1 divergent from Sabin 2), sporadically found in settings of high OPV coverage.
Here, we describe epidemiologic characteristics of the outbreak of cVDPV2 infection in Nigeria during the period from July 2005 through 30 June 2010, constituting the largest and second-longest known cVDPV-associated outbreak [5, [17] [18] [19] [20] [21] . Furthermore, in accord with the findings of Jenkins et al [21] , we compare clinical features of both VDPV2-and pre-VDPV2-associated cases with WPV and non-polio AFP (NP-AFP) cases. We then assess risks of the emergence and spread of cVDPV2 in northern Nigeria and discuss measures needed to prevent further cVDPV outbreaks.
METHODS

Background
Nigeria, the most populous country in Africa (population, 140 million) [22] , has a population growth rate of 2.4% [23] . Pop [25, 26] . The RI program, begun in 1979, includes 4 doses of tOPV given at birth and at 6, 10, and 14 weeks of age. National average coverage for >3 OPV doses (OPV3) rose above 20% in 1986, increased to 55% in 1990, then decreased to 20% in 1999 [27] . SIAs with OPV began in 1997 [28] [31, 32] .
Case Ascertainment and Classification
During 1996-1998, the Nigerian Ministry of Health and the World Health Organization (WHO) instituted an AFP surveillance system to detect paralytic poliomyelitis. Local government area surveillance officers perform investigations of reported AFP cases, which include a limited clinical history, clinical evaluation, and collection of stool specimens for virologic testing; caretakers of case patients with AFP provide a recall history of the total number of OPV doses received prior to paralysis. Clinical reevaluation for residual paralysis at least 60 days after onset is generally performed when stool specimens are inadequate (ie, because of late collection, insufficient material, or improper transport) [34] and is otherwise performed inconsistently. AFP surveillance quality is monitored by WHO performance standards [35] .
In this report, AFP cases are classified as follows: WPV cases, WPV1 or WPV3 isolated from >1 stool specimen (includes VDPV2 and pre-VDPV2 coinfections) [13] ; VDPV2 cases, Sabin 2-related PV with >10 nt VP1 substitutions (.1% divergent) [4, 5] isolated from >1 stool specimen and no WPV isolated; ''pre-VDPV2'' cases, Sabin 2-related PV with 5-9 nt VP1 substitutions (0.5%-1% divergent) isolated from >1 stool specimen and no WPV isolated; and NP-AFP cases, no WPV, VDPV, or pre-VDPV isolated. If stool specimens were inadequate and if the case patient had residual paralysis after 60-days, died, or was lost to follow-up, cases were referred to an expert panel for classification as either polio compatible (excluded from our analyses) or NP-AFP cases. All VDPV2s were vaccine/nonvaccine recombinants and were counted as outbreak cVDPV2s. Among 27 pre-VDPV2s, 21 were vaccine/nonvaccine recombinants typical of cVDPVs [2, 4] whose cases clustered temporally and geographically with the cVDPV2s and were included in our analyses. Six pre-VDPV2 isolates (including 2 from the southern states of Lagos and Anambra) that were nonrecombinant or vaccine/vaccine recombinants were excluded from our analyses. Detailed virologic characterization of all cVDPV2/pre-VDPV2 isolates will be described elsewhere (Burns et al; unpublished data). All AFP cases for which vaccine/nonvaccine recombinant cVDPV2/pre-VDPV2 and WPV were isolated were included in the description of the outbreak time course and geographic distribution but were classified as WPV cases. Because all cVDPV2s and the 21 pre-VDPV2s included were isolated from case patients in northern states, we compared clinical features of WPV and NP-AFP cases from those states only.
Comparisons between case types for categorical variables were made using v 2 tests for homogeneity or exact tests as necessary or using Cochran-Mantel-Haenszel test to control for age. Kruskal-Wallis tests were used for continuous variables. Population density mapping used LandScan (Oak Ridge National Laboratory) estimates for 2007 compiled on a 30$330$ latitude/longitude grid [36] .
Virus Isolation and Characterization
Viruses in stool specimens were isolated in RD and L20B cells in accordance with standard protocols [37] and were characterized by reverse-transcriptase polymerase chain reaction (RT-PCR) assays using enterovirus-specific and poliovirus group-, serotype-, and Sabin strain-specific primer sets [38, 39] and enzyme-linked immunosorbent assays using cross-absorbed hyperimmune sera [37, 40] . Since August 2006, vaccine-related poliovirus isolates were screened for VDPVs using a real-time RT-PCR assay [20] . VDPVs were identified by VP1 sequencing [41] .
Outbreak Trends
Changes in annualized incidence of cVDPV2 and pre-VDPV2 cases for birth cohorts (2000 to mid-2010) were assessed for the period January 2005-June 2010. The denominator for incidence calculations was the sum of annual state-level population estimates based on the 2006 national census adjusted for infant and child survival and population growth [22, 23, 30] .
OPV Population Coverage Estimates
OPV coverage data are available from administrative reporting of routine immunization, coverage surveys [29] [30] [31] [32] [33] [30] was mapped by state to reflect the immunity status against PV2 for the population at risk for WPV, cVDPV2, and pre-VDPV2 early in the outbreak.
Risk Assessment
State-level cumulative incidence rates of cVDPV2/pre-VDPV2 cases were compared with coverage levels and estimates of the proportion of children without polio immunization (OPV0). Correlations of incidence with coverage were assessed using 3 proxies for state-level routine OPV3 coverage: OPV3 history among case patients with NP-AFP aged 6-35 months from 2005, DTP3 coverage from the 2006 NICS (2005 birth cohort), and DTP3 coverage from the 2008 Demographic and Health Survey (2007 birth cohort). The proportion of OPV0 children was also taken from each coverage data source; for surveys, this was estimated as 100% -%DTP1. LOESS, a method using local polynomial regression fitting [42] , was used to describe the correlation between estimated OPV3 coverage (or OPV0) and incidence of cVDPV2/pre-VDPV2 cases. Spearman rank correlation coefficients were used to quantify the strength of correlation.
RESULTS
Descriptive Epidemiology
From July 2005 through June 2010, 315 cVDPV2 cases, 21 pre-VDPV2 cases, and 10 cVDPV2/pre-VDPV2 coinfections detected in WPV cases were identified in Nigeria (Figure 2 Median ages for case patients with cVDPV2, pre-VDPV2, and WPV (including co-infections) were similar (24 months), and case patients were predominantly male (57%-64%) ( Table 1) . The clinical presentations (ie, fever at onset, asymmetric paralysis, rapid progression of paralysis, and number of affected limbs) were also similar for these 3 categories of cases. Among children with 60-day evaluation reported, the proportion with residual paralysis was not significantly different for those with cVDPV2 cases (77%), compared with those who had WPV (85%) or pre-VDPV2 cases (100%) ( Table 1) .
Most case patients with cVDPV2, pre-VDPV2, and WPV were undervaccinated children (Tables 1 and 2 ). Only 43% of patients with cVDPV2, 15% of those with pre-VDPV2, and 28% of those with WPV received >3 doses of OPV; 20% of patients with cVDPV2, 50% of those with pre-VDPV2, and 36% of those with WPV received no OPV dose. By contrast, OPV3 coverage was significantly higher (64%; P , .001) for patients with NP-AFP than all other case types, and the proportion OPV0 was significantly lower (13%; P , .001) when controlled for age.
During the 5 years of emergence and spread, cases were reported from all 7 northwest (NW) zone states, 4 of 6 northeast (NE) zone states, and 5 of 7 north central (NC) zone states (Figures 1 and 3) . The NW zone accounted for 249 cVDPV2 cases (79%) and 17 pre-VDPV2 cases (81%), and 7 of 10 WPVmixed infections; the NE zone accounted for 42 cVDPV2 cases (13%) and 3 pre-VDPV2 cases (14%), and 3 of 10 WPV-mixed infections; and the NC zone accounted for 24 cVDPV2 cases (8%) and 1 pre-VDPV2 case (5%). A major focus of the outbreak was Kano State, which has high population density ( (Figures 2 and 3) . cVDPV2 lineages 1, 3, 4, and 7 were limited to 2-3 cases primarily localized within a single state, but lineages 5 and 6 were associated with 6-7 cases and spread to multiple states (Figure 3 ). Lineage 2, associated with 291 cVDPV2 cases, predominated in the NW zone by late 2006 and spread widely across the northern states into mid-2010. Of 21 pre-VDPV2 isolates, 16 (76%) were ancestral to subsequent cVDPV2 isolates ( Figure 3) ; the remaining 5, including the pre-VDPV2 from mid-2009, were unrelated to each other or to the cVDPV2 isolates and signaled additional independent emergences. 
Risk Assessment
An inverse relationship was found between disease incidence and type 2-containing OPV3 coverage (or DTP3 coverage proxies) by state using coverage data from 2005 NP-AFP cases ( Figure 5A . Some states with particularly high incidence and low coverage clearly stand out; the northern-state annualized incidence of cVDPV2/pre-VDPV2 cases was 0.09 cases per 100,000 persons (n 5 336), yet state-level incidence was as high as 0.23 cases per 100,000 persons in Zamfara (n 5 39) and 0.19 cases per 100,000 persons in Kano (n 5 95).
DISCUSSION
The 336 pre-VDPV2/cVDPV2 cases and the 10 pre-VDPV2/ cVDPV2-WPV coinfections found in northern Nigeria during the period July 2005-June 2010 constitute the largest reported outbreak of cVDPV infection in terms of the number of cases and in geographic extent [5, 17, 20, 21] . Phylogenetic analyses identified >7 independent cVDPV outbreak lineages with a combined 5 years of transmission despite intermittent tOPV SIAs [5, 13] . NOTE. Data are percentage of subjects, unless otherwise indicated. OPV, oral poliovirus vaccine. a Data on variables analyzed are missing for some cases; ,2% of data are missing for any one variable, except that OPV data are missing for 3% of cVDPV2 cases, 4% of pre-VDPV2 cases, 3% of WPV and WPV/cVDPV2 coinfection cases, and 3% of NP-AFP cases. b WPV cases include 8 cases with WPV and cVDPV2 coinfection and 2 cases with WPV and pre-VDPV2 coinfection.
c Determined using the v 2 test, unless otherwise indicated.
d Data available from 1 January through 31 July 2010.
e The Kruskal-Wallis test for comparison of medians was used.
f Although the overall comparison is statistically significant, the only significant pairwise comparisons are between cVDPV2, pre-VDPV2, and WPV with NP-AFP cases.
g Reflects total OPV doses, including tOPV, mOPV1, mOPV3, and bOPV (in 2010). n The overall comparison is statistically significant. Significant pairwise comparisons are seen between cVDPV2 to WPV and, cVDPV2 and WPV to NP-AFP cases.
Our findings are in accord with previous studies suggesting that the key risk factor for cVDPV emergence and spread is low population immunity [4, 10, 44] . Jenkins et al [21] reached similar conclusions using NP-AFP and NICS 2006 data to estimate coverage with type 2-containing OPV. When we attempted to estimate the tOPV coverage threshold necessary to prevent cVDPV2 emergence and spread in northern Nigeria, there were broad inconsistencies in coverage estimates for states by source. The OPV history of persons with NP-AFP by caregiver recall, expected to be higher than DTP3 estimates due to SIA doses, is of uncertain accuracy and representativeness. Although the LOESS curve shapes differed, NICS 2006 and Demographic and Health Survey 2008 data described similar thresholds of tOPV coverage (60% vs 55%, respectively) and of zero-dose (25% vs 20%, respectively). All available data suggest that the tOPV SIAs, despite substantial coverage gaps, were the primary sources of PV2 immunity for the at-risk population in the northern states. Because the only other source of vaccine-induced PV2 immunity was from lowcoverage RI with tOPV, PV2 immunity gaps widened with the emphasis on the use of mOPV1 and mOPV3 in SIAs. The independent emergence of >7 cVDPV2 lineages during [2005] [2006] [2007] [2008] [2009] suggests that population immunity to PV2 fell further below a critical threshold in many areas across the northern states. The burst of cases in January-June 2009 signaled the widening PV2 immunity gap 4 years into the outbreak, particularly among children reaching 2 years of age who had not received tOPV in SIAs during the period October 2007-April 2009. Because of the high immunogenicity of the Sabin 2 vaccine strain [2, 45, 46] , 1 or 2 tOPV SIAs reaching most unvaccinated children should quickly close immunity gaps to PV2 [5, 10] . The sharp decrease in monthly incidence after June 2009 suggests coverage was higher during the tOPV SIAs in May and August 2009 than in previous tOPV SIAs, consistent with trends in WPV incidence, but not yet sufficient to interrupt cVDPV transmission to date [13] .
Most previous cVDPV outbreaks were recognized at least 1 year after initial emergence [9, 18, 44, 47] , because low OPV coverage is usually accompanied by suboptimal AFP surveillance performance. By contrast, AFP surveillance in Nigeria was generally good despite weaknesses in OPV coverage, allowing investigation of early outbreak events, especially the role of pre-VDPVs. Available clinical follow-up data from this report showed that .75% of case patients with cVDPV2 and with WPV AFP had residual paralysis after 60 days, similar to the report of Jenkins et al [21] . This finding is consistent with previous reports of outbreaks of cVDPV1 infection, for which a cumulative 74% of cVDPV-associated AFP cases involved residual paralysis typical of poliomyelitis [9, 18, 44, 47] ; outcome data were not reported from previous outbreaks of cVDPV2 infection [5, 10] . We also found that all case patients with pre-VDPV2 with follow-up data had residual paralysis after 60 days. Thus, both pre-VDPV2s and cVDPV2s were indistinguishable from WPVs in their capacities to cause paralytic poliomyelitis. These data have some limitations in that ,50% of persons with poliovirus-associated cases underwent follow-up examination, and residual paralysis also was reported in a high proportion of the 10% of persons with NP-AFP who had follow-up data.
The finding that 16 of 21 pre-VDPV2s were ancestral to subsequently observed cVDPV2 lineages strongly implicates pre-VDPV2s as outbreak intermediates. Recognition of the critical early role of pre-VDPVs in the outbreak has important implications for global VDPV surveillance. The 1% demarcation in VP1 nt divergence defining VDPVs was established to balance specificity with sensitivity in routine global VDPV surveillance, while accommodating variations in rates and sites of initial nt substitution into the 3 Sabin strain genomes [4, 7, 48] . However, this outbreak demonstrates that the detection of vaccine-related isolates with ,1% VP1 divergence may have epidemiologic importance, especially in areas with known population immunity gaps, particularly for PV2. Routine screening for VDPVs in AFP surveillance by a combination of molecular and antigenic analyses [5, 20, 37] may be suitable for detecting early cVDPV1 and cVDPV3 outbreak isolates, but it may lack sensitivity for detecting cVDPV2s early in outbreaks. New real-time RT-PCR screening procedures consistently flag the Nigerian cVDPV2 and pre-VDPV2 isolates for further analysis [20] (D. Kilpatrick; personal communication). Timely detection of cVDPV emergence will require ongoing, sensitive AFP surveillance combined with epidemiologic and virologic screening and analyses.
The cVDPV outbreak in Nigeria exemplifies the risks accompanying low RI OPV coverage and underscores the need to balance poliovirus immunity to all serotypes in all populations. In countries and areas where tOPV3 coverage in RI programs remains low, achieving high coverage in SIAs using an appropriate mix of mOPVs, bOPV, and tOPV is essential to limit and ultimately stop all poliovirus circulation.
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